Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients
Transplantation
.
2022 Oct 1;106(10):e463-e464.
doi: 10.1097/TP.0000000000004278.
Epub 2022 Aug 4.
Authors
Tara Shertel
1
,
Nicholas W Lange
1
,
David M Salerno
1
,
Jessica Hedvat
1
,
Douglas L Jennings
1
,
Jason Y Choe
1
,
Robert S Brown Jr
2
,
Marcus R Pereira
3
Affiliations
1
Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY.
2
Department of Medicine, Weill Cornell Medicine, New York, NY.
3
Department of Medicine, Vagelos College of Physicians and Surgeons, New York, NY.
PMID:
35939386
PMCID:
PMC9521385
DOI:
10.1097/TP.0000000000004278
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Neutralizing
COVID-19*
Humans
Organ Transplantation*
SARS-CoV-2
Transplant Recipients
Substances
Antibodies, Neutralizing
bebtelovimab